Abstract
Adjuvant therapy in cutaneous melanoma is the standard of care in high-risk patients, including stages IIB, IIC, III and IV (after surgical treatment). Adjuvant therapy options are different, including single-agent immunotherapy, combined immunotherapy, targeted therapy in the patient with BRAF mutation. The choice of treatment option depends on many factors, such as the stage of the disease, previous history of the disease, concomitant disease and patient preferences. This review is a comprehensive summary of published research on the basis of which modern adjuvant therapy is based.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.